The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Venoms as a platform for human drugs: translating toxins into therapeutics
Abstract
INTRODUCTION: An extraordinarily diverse range of animals have evolved venoms for predation, defence, or competitor deterrence. The major components of most venoms are peptides and proteins that are often protease-resistant due to their disulfide-rich architectures. Some of these toxins have become valuable as pharmacological tools and/or therapeutics due to their extremely high specificity and potency for particular molecular targets. There are currently six FDA-approved drugs derived from venom peptides or proteins. AREAS COVERED: This article surveys the current pipeline of venom-derived therapeutics and critically examines the potential of peptide and protein drugs derived from venoms. Emerging trends are identified, including an increasing industry focus on disulfide-rich venom peptides and the use of a broader array of molecular targets in order to develop venom-based therapeutics for treating a wider range of clinical conditions. EXPERT OPINION: Key technical advances in combination with a renewed industry-wide focus on biologics have converged to provide a larger than ever pipeline of venom-derived therapeutics. Disulfide-rich venom peptides obviate some of the traditional disadvantages of therapeutic peptides and some may be suitable for oral administration. Moreover, some venom peptides can breach the blood brain barrier and translocate across cell membranes, which opens up the possibility of exploiting molecular targets not previously accessible to peptide drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Natural products as sources of new drugs over the last 25 years
Newman, D. J., & Cragg, G. M. (2007) · Journal of Natural Products · doi:10.1021/np068054v · Cited by 5,517
The evolving role of natural products in drug discovery
Koehn, F. E., & Carter, G. T. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1657 · Cited by 2,572
An SCN9A channelopathy causes congenital inability to experience pain
Cox, J. J., Reimann, F., Nicholas, A. K., Thornton, G., Roberts, E., Springell, K., Karbani, G., Jafri, H., Mannan, J., Raashid, Y., et al. (2006) · Nature · doi:10.1038/nature05413 · Cited by 1,600
Synthetic therapeutic peptides: science and market
Vlieghe, P., Lisowski, V., Martinez, J., & Khrestchatisky, M. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2009.10.009 · Cited by 1,476
Lessons from 60 years of pharmaceutical innovation
Munos, B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2961 · Cited by 1,207
Lessons from natural molecules
Clardy, J., & Walsh, C. (2004) · Nature · doi:10.1038/nature03194 · Cited by 1,171
The productivity crisis in pharmaceutical R&D
Pammolli, F., Magazzini, L., & Riccaboni, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3405 · Cited by 918
The Toxicogenomic Multiverse: Convergent Recruitment of Proteins Into Animal Venoms
Fry, B. G., Roelants, K., Champagne, D. E., Scheib, H., Tyndall, J. D. A., King, G. F., Nevalainen, T. J., Norman, J. A., Lewis, R. J., Norton, R. S., et al. (2009) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.9.081307.164356 · Cited by 822
Self-citationTherapeutic potential of venom peptides
Lewis, R. J., & Garcia, M. L. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1197 · Cited by 798
Strategies to improve plasma half life time of peptide and protein drugs
Werle, M., & Bernkop-Schnürch, A. (2006) · Amino Acids · doi:10.1007/s00726-005-0289-3 · Cited by 660
Ziconotide: Neuronal Calcium Channel Blocker for Treating Severe Chronic Pain
Miljanich, G. P. (2004) · Current Medicinal Chemistry · doi:10.2174/0929867043363884 · Cited by 607
The Renaissance of Natural Products as Drug Candidates
Paterson, I., & Anderson, E. A. (2005) · Science · doi:10.1126/science.1116364 · Cited by 559
Pallaghy, P. K., Norton, R. S., Nielsen, K. J., & Craik, D. J. (1994) · Protein Science · doi:10.1002/pro.5560031022 · Cited by 523
Fry, B. G. (2005) · Genome Research · doi:10.1101/gr.3228405 · Cited by 486
Tumor Paint: A Chlorotoxin:Cy5.5 Bioconjugate for Intraoperative Visualization of Cancer Foci
Veiseh, M., Gabikian, P., Bahrami, S.-B., Veiseh, O., Zhang, M., Hackman, R. C., Ravanpay, A. C., Stroud, M. R., Kusuma, Y., Hansen, S. J., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3948 · Cited by 422
Drug discovery beyond the ‘rule-of-five’
Zhang, M.-Q., & Wilkinson, B. (2007) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2007.10.005 · Cited by 418
ASIC3, a sensor of acidic and primary inflammatory pain
Deval, E., Noël, J., Lay, N., Alloui, A., Diochot, S., Friend, V., Jodar, M., Lazdunski, M., & Lingueglia, E. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.213 · Cited by 405
Therapeutic peptides: technological advances driving peptides into development
Sato, A. K., Viswanathan, M., Kent, R. B., & Wood, C. R. (2006) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2006.10.002 · Cited by 362
Natural products and combinatorial chemistry: back to the future
Ortholand, J.-Y., & Ganesan, A. (2004) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2004.04.011 · Cited by 336
Therapeutic application of peptides and proteins: parenteral forever?
Antosova, Z., Mackova, M., Kral, V., & Macek, T. (2009) · Trends in Biotechnology · doi:10.1016/j.tibtech.2009.07.009 · Cited by 324
A rational nomenclature for naming peptide toxins from spiders and other venomous animals
King, G. F., Gentz, M. C., Escoubas, P., & Nicholson, G. M. (2008) · Toxicon · doi:10.1016/j.toxicon.2008.05.020 · Cited by 313
Self-citationThe Engineering of an Orally Active Conotoxin for the Treatment of Neuropathic Pain
Clark, R. J., Jensen, J., Nevin, S. T., Callaghan, B. P., Adams, D. J., & Craik, D. J. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.201000620 · Cited by 313
Spider-Venom Peptides as Therapeutics
Saez, N. J., Senff, S., Jensen, J. E., Er, S. Y., Herzig, V., Rash, L. D., & King, G. F. (2010) · Toxins · doi:10.3390/toxins2122851 · Cited by 298
Self-citationMeng, Z., Yang, P., Shen, Y., Bei, W., Zhang, Y., Ge, Y., Newman, R. A., Cohen, L., Liu, L., Thornton, B., et al. (2009) · Cancer · doi:10.1002/cncr.24602 · Cited by 289
Mamelak, A. N., & Jacoby, D. B. (2007) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.4.2.175 · Cited by 273
History of the design of captopril and related inhibitors of angiotensin converting enzyme.
Cushman, D. W., & Ondetti, M. A. (1991) · Hypertension · doi:10.1161/01.hyp.17.4.589 · Cited by 270
A tarantula peptide against pain via ASIC1a channels and opioid mechanisms
Mazzuca, M., Heurteaux, C., Alloui, A., Diochot, S., Baron, A., Voilley, N., Blondeau, N., Escoubas, P., Gélot, A., Cupo, A., et al. (2007) · Nature Neuroscience · doi:10.1038/nn1940 · Cited by 266
Diversity of folds in animal toxins acting on ion channels
MOUHAT, S., JOUIROU, B., MOSBAH, A., DE WAARD, M., & SABATIER, J.-M. (2004) · Biochemical Journal · doi:10.1042/bj20031860 · Cited by 240
From snake venom toxins to therapeutics – Cardiovascular examples
Koh, C. Y., & Kini, R. M. (2012) · Toxicon · doi:10.1016/j.toxicon.2011.03.017 · Cited by 228
Molecular diversity of spider venom
Vassilevski, A. A., Kozlov, S. A., & Grishin, E. V. (2009) · Biochemistry (Moscow) · doi:10.1134/s0006297909130069 · Cited by 204
Were arachnids the first to use combinatorial peptide libraries?
Sollod, B. L., Wilson, D., Zhaxybayeva, O., Gogarten, J. P., Drinkwater, R., & King, G. F. (2005) · Peptides · doi:10.1016/j.peptides.2004.07.016 · Cited by 200
Self-citationVenomics: a new paradigm for natural products-based drug discovery
Vetter, I., Davis, J. L., Rash, L. D., Anangi, R., Mobli, M., Alewood, P. F., Lewis, R. J., & King, G. F. (2011) · Amino Acids · doi:10.1007/s00726-010-0516-4 · Cited by 197
Self-citationIsosteric replacement of sulfur with other chalcogens in peptides and proteins
Moroder, L. (2005) · Journal of Peptide Science · doi:10.1002/psc.654 · Cited by 191
α-Selenoconotoxins, a New Class of Potent α7 Neuronal Nicotinic Receptor Antagonists
Armishaw, C. J., Daly, N. L., Nevin, S. T., Adams, D. J., Craik, D. J., & Alewood, P. F. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512419200 · Cited by 184
Satkunanathan, N., Livett, B., Gayler, K., Sandall, D., Down, J., & Khalil, Z. (2005) · Brain Research · doi:10.1016/j.brainres.2005.08.009 · Cited by 180
Remarkable inter- and intra-species complexity of conotoxins revealed by LC/MS
Davis, J., Jones, A., & Lewis, R. J. (2009) · Peptides · doi:10.1016/j.peptides.2009.03.019 · Cited by 173
Venomics as a drug discovery platform
Escoubas, P., & King, G. F. (2009) · Expert Review of Proteomics · doi:10.1586/epr.09.45 · Cited by 172
Self-citationVenomics: unravelling the complexity of animal venoms with mass spectrometry
Escoubas, P., Quinton, L., & Nicholson, G. M. (2008) · Journal of Mass Spectrometry · doi:10.1002/jms.1389 · Cited by 158
Anticancer potential of animal venoms and toxins.
Gomes, A., Bhattacharjee, P., Mishra, R., Biswas, A. K., Dasgupta, S. C., & Giri, B. (2010) · PubMed · Cited by 156
Muttenthaler, M., & Alewood, P. F. (2008) · Journal of Peptide Science · doi:10.1002/psc.1075 · Cited by 151
Fox, J. W., & Serrano, S. M. T. (2007) · Current Pharmaceutical Design · doi:10.2174/138161207782023739 · Cited by 146
Kesavan, K. P., Ratliff, J., Johnson, E. W., Dahlberg, W. K., Asara, J. M., Misra, P., Frangioni, J. V., & Jacoby, D. B. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.066092 · Cited by 144
Engineering a Stable and Selective Peptide Blocker of the Kv1.3 Channel in T Lymphocytes
Pennington, M. W., Beeton, C., Galea, C. A., Smith, B. J., Chi, V., Monaghan, K. P., Garcia, A., Rangaraju, S., Giuffrida, A., Plank, D. W., et al. (2009) · Molecular Pharmacology · doi:10.1124/mol.108.052704 · Cited by 138
Australian funnel-web spiders: master insecticide chemists
Tedford, H. W., Sollod, B. L., Maggio, F., & King, G. F. (2004) · Toxicon · doi:10.1016/j.toxicon.2004.02.010 · Cited by 133
Self-citationA novel analgesic toxin (hannalgesin) from the venom of king cobra (Ophiophagus hannah)
Pu, X. C., Wong, P. T.-H., & Gopalakrishnakone, P. (1995) · Toxicon · doi:10.1016/0041-0101(95)00096-5 · Cited by 117
Smith, H. S. (2008) · Pain Physician · doi:10.36076/ppj.2008/11/s89 · Cited by 113
Lee, C. Y. W., Chen, H. H., Lisý, O., et al. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009336233 · Cited by 111
Smith, J. J. L., Hill, J. M., Little, M. J., Nicholson, G. M., King, G. F., & Alewood, P. F. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1103501108 · Cited by 107
Self-citationLevy, D. E., del Zoppo, G. J., Demaerschalk, B. M., Demchuk, A. M., Diener, H., Howard, G., Kaste, M., Pancioli, A., Ringelstein, E. B., Spatareanu, C., et al. (2009) · Stroke · doi:10.1161/strokeaha.109.565119 · Cited by 101
Pharmaceutical R&D: the road to positive returns
David, E., Tramontin, T., & Zemmel, R. W. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2948 · Cited by 94
Akcan, M., Stroud, M. R., Hansen, S. J., Clark, R. J., Daly, N. L., Craik, D. J., & Olson, J. M. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101018r · Cited by 94
Targeting ionotropic receptors with polyamine-containing toxins☆
Mellor, I. R., & Usherwood, P. N. R. (2004) · Toxicon · doi:10.1016/j.toxicon.2004.02.003 · Cited by 92
Favreau, P., Menin, L., Michalet, S., Perret, F., Cheneval, O., Stöcklin, M., Bulet, P., & Stöcklin, R. (2006) · Toxicon · doi:10.1016/j.toxicon.2006.01.020 · Cited by 92
Pimenta, A. M. C., & de Lima, M. E. (2005) · Journal of Peptide Science · doi:10.1002/psc.701 · Cited by 90
Spider Venom Toxin Protects Plants from Insect Attack
Khan, S. A., Zafar, Y., Briddon, R. W., Malik, K. A., & Mukhtar, Z. (2006) · Transgenic Research · doi:10.1007/s11248-006-0007-2 · Cited by 89
Brust, A., Palant, E., Croker, D. E., Colless, B., Drinkwater, R. D., Patterson, B., Schroeder, C. I., Wilson, D. T. R., Nielsen, C. K., Smith, M. T., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9003413 · Cited by 87
Deer, T. R., Malinowski, M. N., & Kim, C. H. (2019) · Pain · doi:10.1007/978-3-319-99124-5_188 · Cited by 85
Aroui, S., Ram, N., Appaix, F., Ronjat, M., Kénani, A., Pirollet, F., & WAARD, M. M. D. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9782-1 · Cited by 82
α-Conotoxins as selective probes for nicotinic acetylcholine receptor subclasses
Janes, R. W. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.01.013 · Cited by 81
Barnett, A. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.15.2593 · Cited by 79
Cyclization of conotoxins to improve their biopharmaceutical properties
Clark, R. J., Akcan, M., Kaas, Q., Daly, N. L., & Craik, D. J. (2010) · Toxicon · doi:10.1016/j.toxicon.2010.12.003 · Cited by 74
STRUCTURE AND FUNCTION OF INSECTICIDAL NEUROTOXINS FROM AUSTRALIAN FUNNEL-WEB SPIDERS
King, G. F., Tedford, H. W., & Maggio, F. (2002) · Journal of Toxicology Toxin Reviews · doi:10.1081/txr-120014409 · Cited by 74
Self-citationFry, B. G., Wickramaratana, J., Lemme, S., Beuve, A., Garbers, D. L., Hodgson, W. C., & Alewood, P. F. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.11.171 · Cited by 72
Kolosov, A., Goodchild, C. S., & Cooke, I. (2009) · Pain Medicine · doi:10.1111/j.1526-4637.2009.00741.x · Cited by 63
Positron emission tomography imaging of prostate cancer
Hong, H., Zhang, Y., Sun, J., & Cai, W. (2009) · Amino Acids · doi:10.1007/s00726-009-0394-9 · Cited by 62
Eptifibatide: a potent inhibitor of the platelet receptor integrin glycoprotein IIb/IIIa
Tcheng, J. E., & O’Shea, J. C. (2002) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.3.8.1199 · Cited by 62
Gowd, K. H., Yarotskyy, V., Elmslie, K. S., Skalicky, J. J., Olivera, B. M., & Bulaj, G. W. (2010) · Biochemistry · doi:10.1021/bi902137c · Cited by 61
Exenatide once weekly for the treatment of type 2 diabetes
Malone, J., Trautmann, M., Wilhelm, K., Taylor, K., & Kendall, D. M. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902766802 · Cited by 55
µ-Conotoxins as Leads in the Development of New Analgesics
Norton, R. S. (2010) · Molecules · doi:10.3390/molecules15042825 · Cited by 55
Desmoteplase: discovery, insights and opportunities for ischaemic stroke
Medcalf, R. L. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01514.x · Cited by 54
Earl, S., Masci, P. P., de Jersey, J., Lavin, M. F., & Dixon, J. (2010) · Toxicon · doi:10.1016/j.toxicon.2010.12.010 · Cited by 50
Proteome and peptidome profiling of spider venoms
Liang, S. (2008) · Expert Review of Proteomics · doi:10.1586/14789450.5.5.731 · Cited by 50
Minea, R. O., Helchowski, C. M., Zidovetzki, S., Costa, F. K., Swenson, S. D., & Markland, F. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010929 · Cited by 49
The discovery of captopril: from large animals to small molecules
Opie, L. H., & Kowollik, H. (1995) · Cardiovascular Research · doi:10.1016/0008-6363(95)00006-2 · Cited by 45
Reid, P. F. (2007) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.v27.i4.10 · Cited by 40
Wei, J.-M., Zhu, M., Zhang, Z., Zhen-geng, J. I. A., He, X., Wan, Y., Wang, S., Dian-rong, X. I. U., Tang, Y., Jie, L. I., et al. (2010) · Chinese Medical Journal · doi:10.3760/cma.j.issn.0366-6999.2010.05.016 · Cited by 32
Batroxobin Mobilizes Circulating Endothelial Progenitor Cells in Patients With Deep Vein Thrombosis
Zhang, L., Lu, S., Li, L., Tao, Y.-G., Wan, Y. L., Senga, H., Yang, R., & Han, Z. (2009) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029609347903 · Cited by 26
Dove, A. (2008) · Nature Biotechnology · doi:10.1038/nbt1108-1213 · Cited by 19
Tirofiban in acute coronary syndromes
Menozzi, A., Merlini, P. A., & Ardissino, D. (2005) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.3.2.193 · Cited by 14
Marí, F., & Tytgat, J. (2010) · Elsevier eBooks · doi:10.1016/b978-008045382-8.00638-9 · Cited by 4
Cited by
Therapeutic Peptides: Current Applications and Future Directions
Wang, L., Wang, N., Zhang, W., Cheng, X., Yan, Z., Shao, G., Wang, X., Wang, R., & Fu, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00904-4 · Cited by 2,131
Trends in peptide drug discovery
Muttenthaler, M., King, G. F., Adams, D. J., & Alewood, P. F. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00135-8 · Cited by 1,964
Self-citationThe Current State of Peptide Drug Discovery: Back to the Future?
Henninot, A., Collins, J. C., & Nuss, J. M. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00318 · Cited by 1,113
Complex cocktails: the evolutionary novelty of venoms
Casewell, N. R., Wüster, W., Vonk, F. J., Harrison, R. A., & Fry, B. G. (2013) · Trends in Ecology & Evolution · doi:10.1016/j.tree.2012.10.020 · Cited by 993
Cragg, G. M., & Pezzuto, J. M. (2016) · Medical Principles and Practice · doi:10.1159/000443404 · Cited by 798
Metadata
- Authors
- King, G. F.
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa UK Limited
- Published
- 2011-09-23
- Volume
- 11
- Issue
- 11
- Pages
- 1469-1484
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- OpenAlex
- W2075127809
- Cited by
- 516
- References
- 82
- FWCI
- 15.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.